Phase III

Phase III clinical trials confirm therapeutic efficacy, monitor adverse reactions, and compare investigational treatments to standard-of-care options in large patient populations, typically involving 300-3,000 participants across multiple sites. These definitive studies generate the comprehensive evidence regulatory authorities require for marketing approval decisions, representing the final validation before therapies reach patients worldwide.

Designed as randomised, controlled trials, Phase III studies rigorously evaluate whether new therapeutics provide clinically meaningful benefits that outweigh potential risks. Investigators measure primary endpoints aligned with regulatory guidance such as overall survival in oncology or glycaemic control in diabetes. These trials also assess secondary endpoints, quality of life measures, and long-term safety profiles. The biopharmaceutical industry invests billions annually in Phase III programmes, with approximately 58% of therapies successfully completing Phase III, failure often stemming from insufficient efficacy or unexpected safety concerns. Regulatory innovations including accelerated approval pathways and breakthrough therapy designations have shortened timelines for promising candidates, enabling faster patient access to transformative treatments.